U lcerative colitis (UC) is a chronic relapsing and remitting inflammatory disease of the colon. Accurate assessment of disease activity is a vital process for disease management and improving long-term outcomes. Although endoscopic assessment provides the most definitive and objective assessment of disease activity, it is invasive, costly, and has limited availability.
Patient-reported outcomes (PRO), symptoms reported directly by the patient without a clinician's interpretation, are commonly used to provide information about disease activity for chronic disorders. PROs are important determinants of the illness experience, particularly from a patient's point of view. The inclusion of a PRO also is mandated by the Food and Drug Administration for use in clinical trial designs. 1 The existing literature suggests that rectal bleeding (RB) and increased stool frequency (SF) (PRO2) are the most relevant clinical symptoms in UC. 2 Indeed, the International Organization For the Study of Inflammatory Bowel Disease Stride guidelines recommended resolution of PRO2 as a key clinical treatment target. 2 Multiple clinical activity scores also have been developed for the assessment of disease activity incorporating PRO and additional components, including physician's global assessment, noninvasive laboratory tests, and/or endoscopic scores. These include the noninvasive indices of Seo et al, 3 Simple Clinical Colitis Activity Index (SCCAI or Walmsley et al 4 score), Pediatric UC Activity Index, 5 Lichtiger et al, 6 and Beattie et al 7 scores. In contrast, the Mayo clinical score, 8 Rachmilewitz 9 score (clinical activity index), UC disease activity index, 10 and the Powell-Tuck 11 / St Mark index consist of composite clinical, physician's global assessment, and endoscopic scores. Table 1 summarizes all invasive, noninvasive, and composite indices currently available to describe disease activity in UC.
Emerging literature has suggested that in contrast to Crohn's disease, there may be a better correlation between clinical symptoms and endoscopic assessment in UC, and that endoscopic evaluation contributes little additional information to activity assessment. 17 Therefore, treating UC patients based on reported symptoms may be acceptable in certain clinical scenarios. However, most of the comparisons have been made using a heterogeneous combination of clinical and endoscopic scores. It is within this framework that we aimed to systemically review whether clinical symptoms, and especially the PRO2 score, correlate reliably with endoscopic evaluation for the assessment of disease activity in UC patients.
Methods

Search Strategy
Systematic searches were performed from January 1980 to June 2018 using MEDLINE, EMBASE, Scopus, CENTRAL, and ISI Web of knowledge. Citation selection used a highly sensitive search strategy identifying studies with medical subject headings relating to the following: (1) ulcerative colitis (2) severity of illness index, and (3) invasive and noninvasive scoring systems. Recursive searches, cross-referencing, and subsequent hand-searches were completed.
Trial Selection, Patient Population, and Inclusion-Exclusion Criteria
To be included, studies were required to meet the following criteria: (1) fully published studies comparing PRO2 (rectal bleeding and stool frequency, or other clinical scores) with endoscopy; (2) a diagnosis of UC established by clinical, endoscopic, and/or histologic criteria; (3) endoscopic assessments of UC patients performed at the same time as patient symptom assessment using a score; and (4) observational design (prospective or post hoc analysis of prospectively obtained cohort) or interventional design (randomized or nonrandomized).
Trials comprising only pediatric patients or inpatients were excluded. Guidelines, retrospective case series, case reports, or proceedings from consensus conferences also were excluded.
Choice of Outcomes
The primary outcome measure was the correlation between PRO2, represented by the presence or absence
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Background Accurate assessment of disease activity is required to optimize outcomes of the treat-to-target management strategy for patients with ulcerative colitis (UC). We performed a systematic review to determine if symptoms of UC correlate with findings from endoscopy.
Findings
In an analysis of data from 23 articles, we found results of clinical indices used to evaluate UC activity to correlate with endoscopic features. Composite clinical measures including rectal bleeding and stool frequency had moderate to strong correlations with endoscopic disease activity; absence of rectal bleeding identified patients with inactive disease with higher levels of sensitivity than normalization of stool frequency.
Implications for patient care
Inclusion of clinical activity parameters, such as the combination of rectal bleeding and stool frequency, might improve assessment of UC activity and prioritize patients for endoscopic evaluation in resourcelimited settings. However, limitations exclude adaptation of symptom-based treatment. of RB and/or changes in SF with endoscopic activity in UC.
We assessed secondarily the correlation between clinical score and endoscopic activity for patients with active vs inactive disease, localization of the disease, and medications used.
Data Analysis
Definitions used for endoscopic activity or remission, clinical activity or remission, and PRO2 are summarized in Table 1 .
Given the heterogeneous nature of the collected information, the results were analyzed principally in a qualitative fashion.
Studies assessed the scale validity to a clinical or endoscopy outcome by reporting sensitivity or specificity. Other studies reported the Pearson or Spearman correlation coefficients that measure the strength of association between the clinical or endoscopic scales and the direction of the relationship, whereas other studies also assessed the correlation between the scales.
The reported comparisons and outcomes were expected to vary in each study, precluding performing a meta-analysis.
Validity Assessment
Two investigators (S.R. and C.-Y.C.) assessed citation eligibility for each publication, with discrepancies resolved by a third independent reviewer (P.L.L.).
Quality Assessment
Two authors (S.R. and C.-Y.C.) assessed the quality of included studies using the Quality Assessment of Diagnostic Accuracy Studies 2 tool ( Figure 1 ). Any disagreements were resolved through discussion with a third senior author (P.L.L.).
Results
Included Studies
Of 3449 citations, 23 studies (1 randomized controlled trial and 22 observational studies) fulfilled our inclusion criteria (n ¼ 3320 patients) ( Figure 2 , Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram). The indication for endoscopy was for the assessment of active disease in 18 studies.
Clinical scales for UC activity assessment included SCCAI, partial Mayo, Rachmilewitz, 9 Seo et al 3 index, and PRO2 (rectal bleeding and increased stool frequency). Endoscopic scales as comparators comprised the Ulcerative Colitis Colonoscopic Index of Severity, 15 Mayo, 8 Rachmilewitz, 9 St Mark's index, 11 Baron et al, 18 and Ulcerative Colitis Endoscopic Index of Severity. 14 Comparison methods between clinical and endoscopic scores were conducted using correlation coefficient in 18 studies, while agreement coefficient and area under the receiver operating characteristic curve (AUC) were determined in 1 and 2 studies, respectively.
Study Quality Assessment: Quality Assessment of Diagnostic Accuracy Studies-2
Selected studies showed a high applicability concern in patient selection (ie, moderate to severe disease) because only active or newly diagnosed UC patients with active disease were included. The risk of bias was unclear for patient selection, index test, reference standard, and flow and timing. High risk was found for the latter in 1 study in which not all of the initial patients were included in the final analysis.
Association Between Clinical Symptoms and Endoscopy in the Different Study Populations
Patient-reported outcomes 2: rectal bleeding and stool frequency. Overall, 4 studies provided information on PRO2 and other clinical indices (Lewis et al, 19 Dhanda et al, 20 Azzolini et al, 12 and Seo et al 3 ) and all showed that the PRO2 correlation with endoscopic disease activity was stronger or at least comparable with established clinical indices with a Spearman correlation coefficient varying from 0.64 to 0.89 (P < .01). Two post hoc analyses of clinical trials (Jharap et al, 21 Jairath et al 1 ) and 1 prospective cohort study (Colombel et al 22 ) compared PRO2 independently of composite clinical indices with endoscopic assessment. These studies also showed that PRO2 correlated well and had comparable diagnostic performance with clinical indices in assessing endoscopic activity (sensitivity, 0.21-0.62; specificity, 0.77-0.98; AUC, 0.62-0.9). Table 2 contains the complete details of the included studies.
The study by Jairath et al 1 showed that the combined use of RB and SF had a superior AUC than using these items separately (AUC, 0.9 vs 0.78-0.85). Similarly, Jharap et al 21 also suggested higher specificity using combined RB and SF score (specificity, 0.98 vs 0.59-0.94).
Insufficient data were available to compare the diagnostic capacity of RB vs SF. However, Jharap et al 21 described that RB was associated with a lack of ulcer healing whereas stool frequency may remain increased despite mucosal healing. Colombel et al 22 similarly reported that endoscopically inactive disease was associated with the absence of RB but not with complete normalization of SF. When identifying UC patients with inactive disease, RB scores were superior to SF scores and the combination (sensitivity/specificity: Mayo Clinic endoscopic subscore [MCSe], 0/1; RB, 0.77/0.81; SF, 0.62/0.95; RB þ SF, 0.54/0.95; MCSe, 0; RB, 0.87/0.66; SF, 0.76/0.83; RB þ SF, 0.68/0.86). Across different 19 Dhanda et al, 20 Jharap et al, 21 Scaioli et al, 23 Seo et al, 3 Achitei et al, 24 Mirpour et al, 25 Jairath et al 1 ), whereas 15 studies included patients with both active and inactive disease (Bodelier et al, 26 Schoepfer et al, 27 Pagnini et al, 28 Beattie et al, 7 Azzolini et al, 12 Hirai et al, 29 Langhorst et al, 30 Arai et al, 31 Higging et al, 32 Ricanek et al, 33 Samuel et al, 34 Taleban et al, 35 Falvey et al, 36 Chen et al, 37 and Colombel et al 22 ) . Unfortunately, the published data do not provide information for active vs inactive disease separately. No study examined only patients in remission.
All of these studies consistently showed a good correlation between noninvasive indices and endoscopy results in studies of active patients only, or in studies with both active patients and patients in remission. However, 2 studies (Pagnini et al 28 and Hirai et al 29 ) suggested that the correlation between clinical and endoscopic indices might be stronger among patients with lower levels of disease activity. For example, in Hirai et al 29 the correlations between the clinical indices and endoscopic indices were weaker (Spearman correlation coefficient, 0.29-0.47) when the disease activity in the UC patients was high, whereas with a decrease in disease activity after treatment, the positive correlations among indices was stronger (Spearman correlation coefficient, 0.53-0.84). See Supplementary Table 1 for detailed data on referenced studies.
Localization. The majority of studies included patients with variable disease extent. Four studies (Dhanda et al, 20 Jharap et al, 21 Beattie et al, 7 Table 1 ).
Ulcerative colitis medications. No study compared the correlation between clinical and endoscopic indices specific to different treatment regimens.
Discussion
This systematic narrative review aimed to comprehensively examine the use of clinical indices, including PRO2, compared with endoscopic assessment of UC disease activity: it has shown a consistent correlation between clinical scores, including patient-reported outcomes of RB and SF, with endoscopic disease activity in the UC population. The diagnostic performance between established clinical indices and RB/SF also seem to be comparable, suggesting that the assessment of UC patients could be simplified to the use of these 2 parameters only. A recent meta-analysis by Narula et al 17 also has shown that normalization of these 2 outcomes indicates a low likelihood of disease activity, potentially rendering endoscopic assessment unnecessary in certain situations. This meta-analysis included a post hoc analysis of 4 randomized controlled trials and a prospective cohort study published before February 2017. A combined RB and SF subscore of 0 identified patients in endoscopic remission with a pooled sensitivity value of 36% (95% CI, 22%-54%), a specificity value of 96% (95% CI, 91%-98%), a positive likelihood ratio of 8.4 (95% CI, 5.5-12.8), and a negative likelihood ratio of 0.66 (95% CI, 0.53-0.84). This study, however, was limited by the significant heterogeneity among the included studies and potential uncontrolled biases because most of the data were obtained from post hoc analyses. Furthermore, discrepancy between RB and SF also was identified in this meta-analysis, showing that the presence of RB is unlikely in the setting of endoscopic remission, whereas SF may not necessarily normalize. The physiological nature of this discrepancy remains unexplained. This potentially could be related to persistent histologic disease activity, altered intestinal permeability, or concomitant irritable bowel syndrome. 38 In addition, this also may be associated with altered colonic physiology in the setting of chronic inflammation. Long-standing UC can result in fibromuscular proliferation, submucosal fibrosis and reduplication of the muscularis mucosa, as well as changes to the neuromuscular components, which in turn lead to morphologic changes and intestinal dysmotility. 39 There also may be a time lag between mucosal healing and resolution of symptoms. Although the results of this narrative review support the combined use of these 2 PRO parameters, their diagnostic yield individually remains to be validated. Finally, all of the PRO studies set a stringent cut-off point of no RB and SF when correlating with endoscopic remission. On the other hand, these studies lack sufficient granularity to compare varying levels of specific PRO cut-off points with the degree of endoscopic activity other than that there is a positive correlation. There also were no data showing what degree of PRO score change would reflect clinically significant improvement in endoscopic inflammation and thus could be targeted to guide treatment optimization. Even though the heterogeneous nature of the included studies reported in this article precluded a more rigorous statistical analysis being performed, the diagnostic performance of PRO2 and clinical indices remains consistent across various patient populations, different clinical settings, and levels of disease activity. The results of this review also are strengthened by the inclusion of a large number of relevant and up-to-date good-quality studies. Indeed, several studies did show that endoscopic assessment contributed little to the variance of disease activity in factor analysis. 20, 32 Therefore, use of noninvasive markers may lead to more efficient and potentially more cost effective clinical management strategies, as well as having a beneficial impact on clinical trials.
Whether disease location influences the diagnostic accuracy of noninvasive indices remains to be determined. The existing literature is insufficiently robust to address this issue. In addition, some of the clinical indices have shown strong construct validity, test-retest reliability, and responsiveness to change 7, 40 ; further strengthening their use in clinical practice.
However, despite the consistent correlation between PRO measures and endoscopic activity, treating UC patients according to symptomatology alone may not achieve optimal clinical outcomes. First, a subset of patients with endoscopic activity would not show significant changes in RB and SF, therefore this would lead to undertreatment of this particular population, or vice versa lead to overtreatment of patients. Furthermore, cumulative evidence in recent years has shown potential superior outcomes with histologic remission over endoscopic mucosal healing and perhaps this will be considered as the ultimate treatment target in the future. Histologic disease activity such as basal plasmocytosis has been shown to be associated independently with clinical relapse and risk of colectomy. 41, 42 In addition, resolution of histologic inflammation may lead to a reduction in hospitalization, corticosteroid use, surgical intervention, and even colorectal malignancy risks. 43 Further definitive and longitudinal comparison of outcomes between histologic and endoscopic remission as well as correlation between PRO measures and histologic remission are eagerly awaited; this should assist us in determining the optimal treatment target and whether PRO can be used as a surrogate tool in the treatment algorithm. Finally, because there are multiple immunomodulatory agents targeting various inflammatory pathways currently available for the treatment of UC, optimal timing to assess treatment response for each class may not be identical and needs to be determined further.
Fecal calprotectin has been shown to be a reliable noninvasive independent biomarker for assessing UC disease activity, mucosal healing, and possibly histologic remission. 44, 45 Therefore, perhaps the diagnostic accuracy of PRO could be strengthened further with the combined use of calprotectin testing. Currently, there are limited data in directly comparing the combined use of PRO and calprotectin as a potential surrogate marker for endoscopic assessment. Future analysis could assist in advancing the use of noninvasive tools in determining disease activity.
Endoscopic and clinical assessment also may have been limited by interobserver variability. Sigmoidoscopy was often the main endoscopic assessment, which may not be representative of the entire colon, although the distal colon tends to be more severe such as in those with concurrent primary sclerosing cholangitis or on rectal topical therapy.
Conclusions
Clinical assessment and patient-reported outcome, especially with the normalization of rectal bleeding and stool frequency, may be helpful in determining UC disease remission. Therefore, the use of endoscopic evaluation may be prioritized in select clinical situations, particularly those in which access is limited owing to resource-or patient-related matters. Although the ultimate treatment target in UC is to be elucidated, the inherent challenges associated with treating patients according to symptomatology alone preclude its adaptation in the current management algorithm.
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